5:37 PM
 | 
May 12, 2016
 |  BC Extra  |  Clinical News

Bayer halts Adempas trial on safety concerns

Bayer AG (Xetra:BAYN) said it stopped the 147-patient Phase IIb RISE-IIP study of Adempas riociguat to treat pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP) after the study's independent DMC "observed that patients...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >